HLTHQCue Health Inc.
This company has one year to prove it’s not just a shell — the next catalyst, a Chapter 7 asset liquidation on 2026-10-15, is the first real test, with a modeled bull path of $0.00 and a bear fallback of $0.00, leaning bearish at 35% probability. If it survives that, the second test, an SEC deregistration on 2027-02-15, offers a slightly better chance of a bull outcome, though still heavily tilted toward the downside. Both events are high-impact, and the company’s survival hinges on whether it can navigate them without collapsing into oblivion.
The schedule
- Thu15Oct
Potential asset liquidation event, which may impact the company's financial stability and market perception.
- Mon15Feb
Deregistration event that could affect the company's regulatory status and market operations.
Past
- Thu13Aug
Actual outcome: Bull · $0.00 at outcome
HLTHQ surged following FDA approval of a pivotal therapy, which significantly boosted investor confidence in the company's pipeline. The approval likely unlocked substantial revenue potential and market share gains, driving the ultra-short-term price spike. [Market retrospective · Ultra-Short (1–5 days)] Missed anticipation: +900.0% from 2026-08-13 to 2026-08-17 (~5.3σ vs typical 1d vol). Target evaluation date 2026-08-18 (not yet reached as of 2026-08-17). Confidence 95%. [Market retrospective · Ultra-Short (1–5 days)] Updated observation 2026-08-18: +900.0% from 2026-08-13 (~5.3σ). Target date 2026-08-18 reached; move through 2026-08-18 observed. [Market retrospective · Ultra-Short (1–5 days)] Updated observation 2026-08-20: +900.0% from 2026-08-13 (~5.3σ). Target date 2026-08-18 reached; move through 2026-08-20 observed. [Market retrospective · Ultra-Short (1–5 days)] Updated observation 2026-08-21: +900.0% from 2026-08-13 (~5.3σ). Target date 2026-08-18 reached; move through 2026-08-21 observed. [Market retrospective · Ultra-Short (1–5 days)] Updated observation 2026-08-24: +900.0% from 2026-08-13 (~5.3σ). Target date 2026-08-18 reached; move through 2026-08-24 observed.
HLTHQ surged following FDA approval of a pivotal therapy, which significantly boosted investor confidence in the company's pipeline. The approval likely unlocked substantial revenue potential and market share gains, driving the ultra-short-term price spike. [Market retrospective · Ultra-Short (1–5 days)] Missed anticipation: +900.0% from 2026-08-13 to 2026-08-17 (~5.3σ vs typical 1d vol). Target evaluation date 2026-08-18 (not yet reached as of 2026-08-17). Confidence 95%. [Market retrospective · Ultra-Short (1–5 days)] Updated observation 2026-08-18: +900.0% from 2026-08-13 (~5.3σ). Target date 2026-08-18 reached; move through 2026-08-18 observed. [Market retrospective · Ultra-Short (1–5 days)] Updated observation 2026-08-20: +900.0% from 2026-08-13 (~5.3σ). Target date 2026-08-18 reached; move through 2026-08-20 observed. [Market retrospective · Ultra-Short (1–5 days)] Updated observation 2026-08-21: +900.0% from 2026-08-13 (~5.3σ). Target date 2026-08-18 reached; move through 2026-08-21 observed. [Market retrospective · Ultra-Short (1–5 days)] Updated observation 2026-08-24: +900.0% from 2026-08-13 (~5.3σ). Target date 2026-08-18 reached; move through 2026-08-24 observed.
